Cadrenal Therapeutics

Cadrenal Therapeutics is a biopharmaceutical company developing a late-stage novel therapy, ticarfarin, with orphan drug designation for the prevention of cardiogenic systemic thromboembolism, commonly known as blood clots, in patients with end-stage renal disease and atrial fibrillation (ESRD+AFib).